Wayback Machine
Nov DEC Jan
Previous capture 20 Next capture
2014 2015 2016
1 captures
20 Dec 15 - 20 Dec 15
sparklines
Close Help
DCV/ASV/BCV Improves Sustained Viral Response in Patients with Chronic HCV GT-1 Infection and Compensated Cirrhosis: UNITY-2 Results

Summary

This article presents data indicating that treatment with an all-oral fixed-dose combination of daclatasvir/asunaprevir/beclabuvir with or without the addition of ribavirin is associated with high rates of sustained viral response to treatment 12 weeks after therapy in patients with chronic compensated cirrhosis and hepatitis C virus genotype 1 infection.

  • Liver Conditions Hepatology Clinical Trials
  • Viral Infections
  • Liver Conditions
  • Hepatology
  • Hepatology Clinical Trials
  • Viral Infections
View Full Text